Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.

Cindy Neuzillet,Bertrand Brieau,Gregory Manuceau,Benoit Rousseau,Laetitia Dahan,Tarek Boussaha,Philippe Vasseur,David Tougeron,Thierry Lecomte,Romain Coriat,Jean-Baptiste Bachet,Jean-Marc Phelip,Aziz Zaanan,Olivier Bouché,Jérôme Desramé,Anne Thirot-Bidault,Isabelle Trouilloud,Christophe Locher,Christophe Tournigand,Astrid Lièvre

Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.

2016

4076Background: There is no validated option beyond GEM-platinum standard 1st-line (L1) chemotherapy (CT) for ABTC. In ovarian and colon cancers, platinum rechallenge demonstrated benefit in patien...

Keywords:

Carcinoma
Pathology
Biliary tract
Gemcitabine
Platinum
Retrospective cohort study
General surgery
Medicine
in patient
Oncology
biliary tract carcinoma
Chemotherapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations